NEW YORK (GenomeWeb News) – Myriad Genetics said after the close of the market Wednesday that it has completed the spin off of Myriad Pharmaceuticals.

The spin off happened on schedule, with Myriad Genetics' shareholders of record as of June 17, receiving a pro-rata dividend of one quarter of a share of Myriad Pharmaceuticals for each share of Myriad Genetics. Fractional shares were paid in cash, the firm said.

As of yesterday, Myriad Genetics has no ownership of Myriad Pharmaceuticals, and the two firms operate completely independently of each other.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.

Aug
20
Sponsored by
Canon BioMedical

This webinar will provide an overview of recent advances in single-cell RNA sequencing from the perspectives of three research organizations.

Aug
27
Sponsored by
Qiagen

This webinar offers a look at how an advanced genetics laboratory implemented and validated a commercial bioinformatics system to help scale its operations.

Sep
18
Sponsored by
Horizon Discovery

In this webinar, Kevin Balbi, head of bioinformatics at Sarah Cannon Molecular Diagnostics, will discuss the validation of targeted sequencing panels on the Ion Torrent platform using Horizon Discovery’s Tru-Q controls.